Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC).
J. Lu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Deng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. Hsu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. L. Kindler
Consultant or Advisory Role - Abbott Laboratories; Amgen; Bristol-Myers Squibb; Clovis Oncology; Merck; Otsuka; Roche
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; ImClone Systems; Merck; POZEN; Roche
J. L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. Bray
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. S. Suzuki
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
E. Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
M. Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen